Crossject S.A. (ALCJ)
Market Closed
10 Aug, 15:30
XPAR 
€
1. 49
-0.01
-0.534%
€
80.16M Market Cap
- P/E Ratio
- Div Yield
102,959 Volume
-0.19 Eps
€ 1.5
Previous Close Want to track ALCJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALCJ closed today lower at €1.49, a decrease of -0.534% from yesterday's close, completing a monthly decrease of -16.7598% or -€0.3. Over the past 12 months, ALCJ stock lost -31.9635%.
ALCJ is not paying dividends to its shareholders.
The last earnings report, released on Mar 25, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Crossject S.A. has completed 5 stock splits, with the recent split occurring on Jun 10, 2025.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XSTU (EUR).
Crossject S.A. (ALCJ) FAQ
What is the stock price today?
The current price is €1.49.
On which exchange is it traded?
Crossject S.A. is listed on XPAR.
What is its stock symbol?
The ticker symbol is ALCJ.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 80.16M.
Has Crossject S.A. ever had a stock split?
Crossject S.A. had 5 splits and the recent split was on Jun 10, 2025.
Crossject S.A. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Mr. Patrick Alexandre CEO | XPAR Exchange | FR0011716265 ISIN |
| France Country | 105 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Crossject Société Anonyme is an innovative healthcare company headquartered in Dijon, France, renowned for developing needle-free injection systems. Established in 2001, the company focuses on revolutionizing the method of administering medications, thereby enhancing patient comfort and safety. Their premiere invention, ZENEO, is a cutting-edge device designed for patient-side management, enabling self-injection of medications without the need for traditional needles. This technology represents a significant advancement in the field of drug delivery, catering to various medical emergencies and treatment requirements.
Products and Services
- Midazolam: A medication intended for the abrupt treatment of epileptic seizures. Crossject delivers this essential drug through their needle-free system, aiming to provide rapid relief in critical situations.
- Naloxone: Developed for the emergency treatment of opioid overdose, Crossject's Naloxone offering is a lifesaver, enabling immediate administration without the complications of traditional injection methods.
- Terbutaline: Terbutaline is designed for treating severe asthma crises. By utilizing the ZENEO device, patients can quickly receive this critical medication during life-threatening asthma attacks.
- Epinephrine: A well-known treatment for anaphylactic shock, Epinephrine is vital for emergency response to severe allergic reactions. Crossject's needle-free solution facilitates instantaneous treatment, which is paramount in saving lives during anaphylaxis.
- Sumatriptan: For those suffering from migraines and cluster headaches, Sumatriptan delivered via ZENEO offers a new level of convenience and speed in managing these debilitating conditions.
- Hydrocortisone: Targeted for acute adrenal crisis, Crossject provides Hydrocortisone in a needle-free format, ensuring rapid administration to counteract this life-threatening condition effectively.
- Methotrexate: For patients dealing with rheumatoid arthritis, Methotrexate via ZENEO provides a less invasive and more manageable therapeutic option, supporting ongoing treatment and quality of life improvements.
Contact Information
Address: 6 Rue Pauline Kergomard
Phone: 33 3 80 54 98 50
Website: https://www.crossject.com
